You just read:

Neurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)

News provided by

Neurocrine Biosciences, Inc.

Apr 11, 2017, 16:52 ET